Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026

The findings address fluid abnormalities missed by bedside examinations in patients with mechanical heart pumps.

Rhea-AI Summary

Daxor (DXR) announced new blood volume analysis study findings and clinician interest following the HFSA 2026 Annual Scientific Meeting. Researchers from Banner University Medical Center presented data on blood volume analysis (BVA), which directly measures plasma volume and red blood cell volume. In patients with left ventricular assist devices or total artificial hearts, standard bedside examinations missed fluid overload and true anemia in 38% of cases. BVA identified these abnormalities, enabling treatment adjustments and a statistically significant improvement in diuresis, or fluid removal through urine (p = 0.02).

A separate 238-patient study examined volume abnormalities in advanced heart failure. Daxor said BVA identified plasma volume reserve depletion linked to red blood cell abnormalities and capillary leak.

Positive

• Minor pointBVA identified abnormalities missed by bedside examinations in 38% of cases among patients with mechanical heart pumps.
• Minor pointBVA-guided treatment adjustments achieved statistically significant improvement in diuresis (p = 0.02).
• Minor pointDaxor said a 238-patient study demonstrated BVA detection of plasma volume reserve depletion.

Negative

• None.

Key Figures

BVA measurement accuracy: Exceeding 95% Bedside examination miss rate: 38% of cases Improvement in patient diuresis: p = 0.02 +1 more

BVA measurement accuracy

Exceeding 95%

BVA diagnostic system

Bedside examination miss rate

38% of cases

Complex heart failure patients with mechanical heart pumps

Improvement in patient diuresis

p = 0.02

Following direct BVA measurement

Study participants

238 patients

Advanced heart failure volume derangements study

Previous Clinical trial Reports

1 past event · Latest: Oct 01

Same Type 1 event

1. Oct 01

   Clinical data presentation

   24h Move

   -2.4%

   Earlier HFSA notice scheduled two posters on the same patient populations and volume abnormalities.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

radiopharmaceutical, diuresis, capillary leak, left ventricular assist device

4 terms

radiopharmaceutical medical

"next-generation blood volume analysis (BVA™) radiopharmaceutical diagnostic system"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

diuresis medical

"statistically significant improvement in patient diuresis"

A physiological or drug-induced increase in urine production and excretion by the kidneys. Diuresis can result from natural changes (e.g., increased fluid intake, hormonal shifts) or from medications called diuretics that alter kidney handling of water and salts; it commonly reduces blood volume and can change electrolyte levels, which is why clinical reports often mention it alongside measures of hydration and serum electrolytes.

capillary leak medical

"red blood cell abnormalities and capillary leak"

Capillary leak is a medical condition in which tiny blood vessels become abnormally porous, allowing fluid and proteins to escape into surrounding tissues; this can cause rapid swelling, low blood pressure and impaired organ function. For investors, it matters because capillary leak can arise as a side effect of drugs or medical devices, influence clinical trial results, trigger safety reviews or recalls, and therefore materially affect a company’s regulatory outlook and stock value.

left ventricular assist device medical

"Inpatient Blood Volume Analysis in Left Ventricular Assist Device and Total Artificial Heart Patients"

A left ventricular assist device (LVAD) is a surgically implanted mechanical pump that helps the heart’s left chamber move blood through the body when the heart is too weak. Think of it as an external engine bolted to a car’s transmission to keep the vehicle running. Investors watch LVADs because their adoption, regulatory approvals, long-term patient outcomes, device durability, and ongoing service and replacement needs drive sales, recurring revenue, and reimbursement patterns in the medical device market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New Clinical Studies Validate BVA^™ Technology in High-Acuity Heart Failure Populations to Enhance Care

OAK RIDGE, TN, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting.

Strong clinician engagement at the conference underscored the need for Daxor’s next-generation blood volume analysis (BVA^™) radiopharmaceutical diagnostic system, driven by its streamlined workflow, rapid result delivery, and industry-leading accuracy exceeding 95%. Daxor highlighted the opportunity that precision volume measurement has to empower effective diagnosis and optimal treatment pathways for patients with heart failure, a syndrome marked by significant volume derangements that are challenging to assess with proxy markers.

Additionally, new clinical data presented by researchers from Banner University Medical Center further validated the essential clinical value of BVA across complex, high-cost patient populations:

• Superior Diagnostic Precision in High-Acuity Patients: The study, "Inpatient Blood Volume Analysis in Left Ventricular Assist Device and Total Artificial Heart Patients," demonstrated that severe heart failure patients with mechanical heart pumps suffer from complex fluid overload and true anemia that standard bedside examinations miss in 38% of cases. Direct BVA measurement unmasked these hidden derangements, enabling care teams to optimize medical therapy and achieve a statistically significant improvement in patient diuresis (p = 0.02).

• Uncovering Critical Heart Failure Volume Targets: The 238-patient study, "Heterogeneity Of Volume Derangements In Advanced Heart Failure: Unmasking Red Blood Cell Volume As A Hidden Driver Of Plasma Volume Phenotypes," concluded that the use of BVA offered the opportunity to “enhance clinical decision making, guide treatment, and improve outcomes.” The study proved BVA’s unique ability to diagnose a critical, previously unmeasurable condition—Plasma Volume Reserve (PVR) depletion—driven by hidden red blood cell abnormalities and capillary leak. The findings solidify BVA as a unique diagnostic tool for precision heart failure care.
  
  

"The latest clinical data presented at HFSA reaffirms what we consistently see in practice: relying on clinical guesswork leads to misdiagnosis in nearly 40% of complex heart failure cases," said Dr. John L. Jefferies, MD, MPH, MBA, Chief Medical Officer of Daxor Corporation. "By providing precise, direct quantification of both plasma volume and red blood cell mass, BVA empowers care teams to move beyond one-size-fits-all diuresis—tailoring targeted therapies that measurably improve decongestion while reducing costly hospital stays and readmissions."

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(516) 222 2560
brets@coreir.com|www.coreir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Daxor's BVA study in patients with mechanical heart pumps show?

BVA identified fluid overload and true anemia that standard bedside examinations missed in 38% of cases. The study involved patients with left ventricular assist devices or total artificial hearts. Treatment adjustments following direct measurement produced a statistically significant improvement in diuresis, or fluid removal through urine, with p = 0.02.

What did Daxor's 238-patient advanced heart failure study find?

Daxor said the 238-patient study demonstrated BVA's ability to identify plasma volume reserve depletion associated with hidden red blood cell abnormalities and capillary leak. The study concluded that BVA offered an opportunity to enhance clinical decision-making, guide treatment and improve outcomes.